Biased Orthosteric Agonism and Allosteric Modulation: Emerging Strategies for Developing New Class of β-Agonists for Obstructive Airway Diseases
American Journal of Respiratory Cell and Molecular Biology · 01.10.2025 · 73 (4) · 489-499
DOI: 10.1165/rcmb.2025-0144tr ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Respiratory Cell and Molecular Biology, online erschienen am 01.10.2025. Verfasst von Sushrut D Shah und 1 weiteren Autor:innen. Beteiligte Einrichtung: Center for Translational Medicine, Jane and Leonard Korman Lung Center, Thomas Jefferson University, Philadelphia, Pennsylvania. Hauptthemen laut MEDLINE: Adrenergic beta-2 Receptor Agonists, Pulmonary Disease, Chronic Obstructive, Adrenergic beta-Agonists, Asthma. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: American Heart Association, NHLBI NIH HHS.
Abstract (Originalsprache)
The obstructive lung diseases (OLDs), such as asthma and chronic obstructive pulmonary disease (COPD) are characterized by bronchoconstriction and difficulty in breathing. β2-adrenergic receptor (β2AR) agonists (β-agonists) represent the most commonly used class of bronchodilators. To enhance their clinical effectiveness, extensive attempts have been made to improve their receptor subtype selectivity and duration of action, resulting in the development of long-acting β-agonists (LABAs) and ultralong-acting β-agonists. Although these drugs effectively alleviate OLD symptoms, concerns have arisen regarding their safety, their reduced therapeutic benefits, and the potential for worsening asthma symptoms. These concerns have led to restrictions on β-agonist use. Recent advances in G protein–coupled receptor (GPCR) pharmacology and biochemistry have introduced new concepts in drug development, such as “biased agonism” and “allosteric modulation.” These advancements stem from a deeper understanding of the molecular interactions between β2ARs and various intracellular proteins (e.g., heterotrimeric G proteins and β-arrestins), which induce a diverse array of functional changes in airway cells. Biased agonism and allosteric modulation offer new avenues for developing the next generation of β-agonists with improved pharmacological properties. This review explores the application of these concepts in developing new β2AR ligands, including orthosteric and allosteric ligands, that selectively enhance therapeutically beneficial Gs signaling while minimizing harmful β-arrestin–mediated effects in airway cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Translational Medicine, Jane and Leonard Korman Lung Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
ORCID-Profile: Sushrut D Shah, Deepak A Deshpande
Förderung
- American Heart Association
- NHLBI NIH HHS
Zitieren
APA
Shah, S. D., & Deshpande, D. A. (2025). Biased Orthosteric Agonism and Allosteric Modulation: Emerging Strategies for Developing New Class of β-Agonists for Obstructive Airway Diseases. American Journal of Respiratory Cell and Molecular Biology, 73(4), 489-499. https://doi.org/10.1165/rcmb.2025-0144tr
Vancouver
Shah SD, Deshpande DA. Biased Orthosteric Agonism and Allosteric Modulation: Emerging Strategies for Developing New Class of β-Agonists for Obstructive Airway Diseases. American Journal of Respiratory Cell and Molecular Biology. 2025;73(4):489-499. doi:10.1165/rcmb.2025-0144tr
BibTeX
@article{Shah2025,
author = {Shah, Sushrut D and Deshpande, Deepak A},
title = {Biased Orthosteric Agonism and Allosteric Modulation: Emerging Strategies for Developing New Class of β-Agonists for Obstructive Airway Diseases},
journal = {American Journal of Respiratory Cell and Molecular Biology},
year = {2025},
volume = {73},
number = {4},
pages = {489--499},
doi = {10.1165/rcmb.2025-0144tr}
}
EUVIMED